How big is the filgrastim market | Stats & Insights 2026

Q: What is the overall size of the filgrastim market?

The filgrastim market was valued at USD 5.2 billion in 2025.

Q: What is the expected CAGR of the filgrastim market through 2032?

The filgrastim market is expected to grow at a CAGR of 8.10% during forecast period.

Q: Which therapeutic areas are driving the filgrastim market?

Oncology, hematology, and chemotherapy-induced neutropenia are key therapeutic drivers.

Q: What are the recent trends shaping the filgrastim industry?

Biosimilar adoption, self-administration solutions, and rising worldwide access are leading trends.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6265

Publication Date: Jul 2025

How big is the filgrastim market?

According to 6Wresearch internal database and industry insights, Global filgrastim market was valued at USD 3.1 Billion in 2025 and is expected to reach USD 5.2 Billion by 2032, growing at acompound annual growth rate of 8.10% during the forecast period.

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global filgrastim market.

View Main Report Schedule Analyst Call

The market growth is supported by increasing cancer incidence, rising chemotherapy procedures, and broader access to biosimilars. Government healthcare initiatives and supportive reimbursement policies are further accelerating the demand for filgrastim worldwide.

Key Growth Factors of the Filgrastim Market

Rising prevalence of cancer and neutropenia-related conditions
Increased chemotherapy usage requiring neutrophil recovery
Expanding approval and adoption of biosimilar filgrastim
Growth in oncology-focused drug development and care access
Favorable reimbursement and supportive government initiatives
Rising awareness in developing countries about neutropenic care

Filgrastim Market Trends

The filgrastim market is witnessing a steady shift towards biosimilar filgrastim, offering cost-effective alternatives to branded drugs. Self-administration delivery formats, such as prefilled syringes and autoinjectors, are enhancing convenience for outpatient treatments. Collaborations between pharma and biotech firms are also fueling R&D activity.

Emerging Developments in the Filgrastim Market

Emerging Developments in the filgrastim market include Companies are expanding their biosimilar portfolios and gaining approvals in emerging markets. Innovations are being seen in formulation stability, longer-acting variants, and subcutaneous delivery mechanisms. Strategic alliances and licensing agreements are driving worldwide expansion and improved market penetration.